Nykode initiates clinical study of "pan-variant" Covid-19 vaccine
Nykode Therapeutics has initiated a clinical trial of its Covid-19 vaccine candidate, which is designed to fight emerging variants like Omicron by targeting T cells. "It's our objective to create a real pan-variant vaccine," says CEO Michael Engsig.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Norwegian biotech firm Nykode Therapeutics, formerly known as Vaccibody, has dosed the first patient in a phase I/II trial involving its T-cell focused vaccine candidate, dubbed VB-D-01, designed to address new Covid-19 variants including Omicron, which are cause for concern the world over.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark defends controversial Covid-19 pill
For subscribers
Bavarian Nordic: We can adapt our vaccine if necessary
For subscribers
